PDP1

Across TCGA pan-cancer cohorts, PDP1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDP1 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PDP1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where PDP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.561	0.878	.015	18	view →
UCEC	OS	Tertile	II,III,IV	0.480	1.000	.017	16	view →
LSCC	DFS	Median	II,III,IV	0.664	0.878	.009	13	view →
CCRCC	OS	Median	III,IV	0.921	0.674	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDP1–PDAC (OS)

Open the PDAC breakdown →